Innovation Theaters Schedule

Thursday, April 16

Morning Break 10:15-11:00 a.m. Theater 1
COPD Management is Evolving: Has Your Practice Caught On?
Sponsored by: GSK
Discover how to identify high-risk patients with COPD, escalate treatment at the right time, and explore treatment options beyond inhaled therapies. Gain insights from a pulmonologist on practical strategies and referral pathways to improve outcomes and stay ahead of exacerbations in modern COPD management.
Abhishek Bhardwaj, MD
Fountain Valley, CA

Morning Break 10:15-11:00 a.m. Theater 2
Tirzepatide: A Dual GIP and GLP-1 Receptor Agonist
Sponsored by: Lilly, USA
Learn about tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, the active ingredient in Zepbound® (tirzepatide) and Mounjaro® (tirzepatide). In this program, we will review clinical efficacy, safety, and dosing and administration information about Zepbound and Mounjaro. Attendees will have the opportunity to ask questions to the speaker at the conclusion of the program.

This program is sponsored by, and the speaker is presenting on the behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.
Carolynn Francavilla, MD
Lakewood, CO

Morning Break 10:15-11:00 a.m. Theater 3
Making Confident Cancer Screening Decisions in Primary Care: CRC and Beyond
Sponsored by: Exact Sciences
This Product Theater discusses established and emerging CRC screening modalities alongside the role of MCED testing in the broader cancer screening continuum. Learn to differentiate options based on test characteristics, patient eligibility, and performance, and explore test integration into primary care workflows.
Aimee Lucas, MD, MS
New York, NY
James Bigham, MD, MPH
Madison, WI

Lunch 12:15-1:00 p.m. Theater 1
Learn How to Reduce the Risk of Major Adverse Cardiovascular Events in Your Patients at High CV Risk Without Prior MI or Stroke
Sponsored by: Amgen
Join our experts for an insightful discussion of clinical evidence and guideline-informed approaches to LDL-C lowering, and explore strategies to reduce the risk of major adverse cardiovascular events in patients at high CV risk without prior MI or stroke. This presentation will include discussion of a treatment option.
Matthew Budoff, MD, FACC, FAHA
Torrance, CA

Lunch 12:15-1:00 p.m. Theater 2
Exploring the Impact of the FreeStyle Libre 3 System on Behavior Change and Clinical Outcomes
Sponsored by: Abbott
Join us to explore the benefits of managing patients with diabetes with CGM technology. Learn about the impact that FreeStyle Libre systems has made on clinical outcomes by driving patient engagement and fostering behavior change.
Jeffrey Unger, MD, FAAFP, FACE, DACD
Rancho Cucamonga, CA

Lunch 12:15-1:00 p.m. Theater 3
Learn About a PrEP Injectable Option
Sponsored by: Gilead Sciences, Inc
Explore the evidence of PrEP as a highly effective but underutilized HIV prevention strategy, including opportunities to further decrease HIV diagnoses, especially in underserved populations. Select details on clinical trial data for an injectable PrEP option and information about its use in clinical practice will also be examined.
Nas Mohamed, MD
San Francisco, CA

Afternoon Break 3:45-4:30 p.m. Theater 2
Discover the Shield™ Blood Test: a Revolutionary Innovation Redefining Colorectal Cancer (CRC) Screening
Sponsored by: Guardant Health
Join us to gain knowledge from leading experts about Shield™ --the first and only FDA-approved blood test for CRC screening with Medicare coverage.
Peyton Berookim, MD, FACG
Beverly Hills, CA

Friday, April 17

Morning Break 10:15-11:00 a.m. Theater 1
Learn About a Trusted and Proven Treatment with Years of Experience in Patients with Uncontrolled Gout
Sponsored by: Amgen
Brian Mandell, MD, PhD
Cleveland, OH

Morning Break 10:15-11:00 a.m. Theater 2
Lipoprotein(a): Recognizing and Managing a Hidden Cardiovascular Risk
Sponsored by: Family Heart Foundation
Lipoprotein(a) or Lp(a) is a powerful, independent, genetically determined risk factor for cardiovascular disease. On a per particle basis, Lp(a) is approximately 6X more atherogenic than LDL-Cholesterol as it has pro-atherosclerotic, pro-thrombotic, and pro-inflammatory properties.

20% of Americans have an elevated level of Lp(a) but the prevalence is even higher in women, African Americans, and South Asians. Most professional societies recommend screening all adults for Lp(a) at least once in a lifetime and yet the diagnosis rate for elevated Lp(a) is currently <5%.

The Family Heart Foundation is a non-profit, patient advocacy organization that supports people with inherited cholesterol disorders, including elevated Lp(a). Please join us for this engaging session to learn more about an emerging risk factor for cardiovascular disease, the latest screening recommendations, and practical management strategies to reduce CV risk in those with elevated Lp(a).
Laurence Sperling, MD, FACC, FACP, FAHA, MASPC
Atlanta, GA
Jay Logu
Family Heart Ambassador

Morning Break 10:15-11:00 a.m. Theater 3
Evidence-Based HIV Prevention in Primary Care: Communication, Options, and Implementation
Sponsored by: ViiV Healthcare
This 45-minute educational presentation will explore practical, guideline informed HIV prevention strategies for primary care clinicians, including approaches to non stigmatizing sexual health discussions and evidence based PrEP decision making. Through didactic content and a moderated panel, faculty will review current oral and long acting injectable PrEP options and discuss implementation considerations within busy primary care settings. Case based discussion and patient perspective will highlight patient centered communication, team based workflows, and strategies to support continuity of care. This non promotional activity is designed to help clinicians translate HIV prevention guidance into routine primary care practice.
Kim Nezianya, PharmD
Houston, TX

Lunch 12:15-1:00 p.m. Theater 1
Beyond A1C: Dexcom G7 15-Day Insights
Sponsored by: Dexcom
See more. Gain perspective. Let glucose data tell the story. Discover how the Dexcom G7 15-Day CGM brings real-time glucose visibility to internal medicine, making it easier to identify patterns, guide treatment decisions, and support efficient, individualized diabetes care. Walk away with actionable tactics, simple conversation cues, and strategies that help you turn continuous data into data-informed decisions for diabetes management.
Aaron King, MD
San Antonio, TX

Lunch 12:15-1:00 p.m. Theater 2
Patient Case Studies for the Pharmacological Management of Overactive Bladder
Sponsored by: Sumitomo Pharma
The presentation guides clinicians through a series of patient scenarios, current evidence from GEMTESA® (vibegron) clinical trials, and practical considerations for personalized treatment selection. Attendees will gain actionable insights into optimizing care for patients—including for older adults and patients with comorbidities—while learning how GEMTESA fits into today’s therapeutic landscape.
Howard Goldman, MD, FACS
Cleveland, OH

Lunch 12:15-1:00 p.m. Theater 3
Helping to Protect Your Eligible Adult Patients Against Pneumococcal Disease Caused by Medically Important Serotypes
Sponsored by: Pfizer
Learn about the burden of pneumococcal disease in adults, the importance of providing direct protection through vaccination, and the critical role of healthcare providers in improving pneumococcal vaccination rates in eligible adults.
Christian Sandrock, MD, MPH, FCCP
Sacramento, CA

Afternoon Break 3:45-4:30 p.m. Theater 2
Explore LYNKUET® (elinzanetant) 60mg capsules: A Newly FDA Approved Treatment Option for Your Appropriate Patients
Sponsored by: Bayer
This session will provide an overview of LYNKUET’s efficacy and safety profile, its mechanism of action, and how to access LYNKUET. Website - https://www.LynkuetHCP.com.
Lisa Larkin, MD, FACP, MSCP IF
Cincinnati, OH

Saturday, April 18

Morning Break 10:15-11:00 a.m. Theater 2
The First Signs Matter: Detecting and Treating Early Symptomatic Alzheimer’s Disease
Sponsored by: Lilly
For patients with early symptomatic Alzheimer’s disease (AD), early detection is critical. Featuring key insights from clinical experience, this impactful program explores a treatment option for early symptomatic AD and why having an action plan to detect AD early is key for improving patient care. 
Armen Moughamian, MD
San Francisco, CA